Complete this short health check to identify the FDA requirements for the areas where you should spend more time revising your current labeling strategies.
Barcodes are used by us all in everyday life, they are on every item we buy and use. However, many of us don’t know ‘what’s behind the lines’.
We like to make our webinars interactive and after our recent webinar on ‘EU MDR’s Impact on Labeling: UDI in Europe and Other Changes’, I thought it would be great to highlight the top five challenges and questions we saw strong responses to
During the webinar we had a couple of live polls, one of which was about the challenges the audience experience in achieving their labeling requirements
Data shows that more than half of all FDA recalls of medical devices have been caused by packaging and/or labeling errors. What is the best way to survive an FDA recall? Make sure you are compliant not only by fixing the recall issue, but preparing for the future.
Here at PRISYM ID, we have recently conducted a survey of international medical device manufacturers, to ascertain their understanding of EU MDR, and the implications of the new regulation on label lifecycle management.
Images are increasingly used in as an integral part of label design to communicate critical information. Their use, therefore, should be bound by the same governance and audit processes as the rest of the label itself.
I recently took part and chaired an interactive session where executives and other medical device industry specialists came together to discuss challenges in a range of areas of labeling development, data and compliance.
The idea of color printing labels on demand has been thrown around the medical device and pharmaceutical market for many years but in reality, most organizations rely on the traditional two-stage color label printing process they know – batch print and over print. But here lays the problem, huge amounts of label stock on the shelf can be costly and quite often wasted.
The clinical trial market is not only global, today it touches more markets than ever before. Increasingly, a key component of this is the need to comply with variable local language labeling requirements, not least in the safe distribution of medicines for clinical trials. With the global map for clinical studies now extensive, information to support the safe and effectual use of trial medicines must be coherent and understandable to the patients receiving them.